<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232241</url>
  </required_header>
  <id_info>
    <org_study_id>HaploMUDStudy</org_study_id>
    <nct_id>NCT04232241</nct_id>
  </id_info>
  <brief_title>Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia</brief_title>
  <official_title>Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis - A Randomized Prospective European Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DKMS Stiftung Leben Spenden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trial Center North (CTC North GmbH &amp; Co. KG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of this open label, two-arm, multicenter, multinational, randomized trial
      is to compare anti-leukemic activity of allogeneic stem cell transplantation for patients
      with acute leukemia in complete remission between a 10/10 HLA matched unrelated donor and a
      haploidentical donor.

      The hypothesis: Haploidentical stem cell transplantation with post cyclophosphamide induces a
      stronger anti-leukemic activity in comparison to 10/10 HLA matched unrelated donor and
      reduces the risk of relapse at 2 years after stem cell transplantation by 10%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives are to assess and compare the safety and efficacy of study treatments
      therapy in both study arms on non-relapse mortality (NRM), relapse-free survival (RFS),
      Overall survival (OS), QOL, toxicity, development of acute and chronic GvDH as well as
      engraftment and chimerism and impact of measurable residual disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse incidence at two years between both arms</measure>
    <time_frame>2 years</time_frame>
    <description>The primary efficacy endpoint will be analyzed using cumulative incidence estimation to assess the subdistribution hazard rates for both treatment groups at two years after accounting for competing risk events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at two years between both arms</measure>
    <time_frame>2 years</time_frame>
    <description>The overall survival at two years between both arms will be presented with Kaplan-Meier's estimates of survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival for all patients assigned to one of the two treatment arms as time to event endpoint</measure>
    <time_frame>through study completion, an average of two yeras</time_frame>
    <description>The overall survival for all patients will be presented with Kaplan-Meier curve. To compare the survival distributions between two arms, log-rank test will be performed, and two-sided p-values will be presented.
If applicable, Cox regression model stratified by the types of leukemia, types of complete remission and conditioning will be performed as sensitivity analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of GVHD/relapse-free survival as Composite endpoint in both arms</measure>
    <time_frame>Starting at day +30 (+/- 3 d) to 24 months (+/- 1 mo) after allogenic stem cell transplantation (SCT)</time_frame>
    <description>The rate of composite endpoint in both arms will be analyzed with the same methods as for the overall survival at two years between both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of non-relapsed mortality (NRM) at 1 and 2 years after allogeneic SCT in both arms</measure>
    <time_frame>At 1 and 2 years after allogeneic SCT</time_frame>
    <description>Due to the existence of competing risk events (persisting disease and relapse), NRM of each arm at 1 and 2 years after allogeneic SCT will be analyzed with the same methods as for the primary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of acute graft-versus-host disease (aGVHD) on day +100 and 1 year (max grade) after allogeneic SCT according to the Glucksberg scale revised by Przepiorka et al. between both arms</measure>
    <time_frame>On day +100 and 1 year (max grade) after allogeneic SCT</time_frame>
    <description>For each time point, the frequency and percentage of aGVHD (maximum grade) of each arm will be presented. To compare the difference between both arms, logistic regression adjusted for covariates and stratification factors will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of chronic graft-versus-host disease (cGVHD) according to the NIH consensus criteria of Jagasia et al. at 1 and 2 years after allogeneic SCT between both arms</measure>
    <time_frame>At 1 and 2 years after allogeneic SCT</time_frame>
    <description>For each time point, the frequency and percentage of cGVHD of each arm will be presented. To compare the difference between both arms, logistic regression adjusted for the stratification factors will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of toxicity of both regimens scored according to the current version of the NCI CTCAE between both arms</measure>
    <time_frame>through study completion, an average of two yeras</time_frame>
    <description>Safety will be analyzed with frequency of patients with AEs as described above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of immune reconstitution between both arms</measure>
    <time_frame>At day 30, 100, 6 months, 1 year and 2 years after allogenic SCT</time_frame>
    <description>Frequency and percentage of patients having immune reconstitution in two arms will be provided. For the comparison between two arms, logistic regression adjusted for the stratification factors will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of full donor chimerism between both arms</measure>
    <time_frame>At day 30, 100, 6 months, 1 year and 2 years after allogenic SCT</time_frame>
    <description>Frequency and percentage of patients having full donor chimerism in two arms will be provided. For the comparison between two arms, logistic regression adjusted for the stratification factors will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Sorror Risk Score on outcome after allogeneic SCT</measure>
    <time_frame>At baseline</time_frame>
    <description>Comorbidity score after Sorror will be assessed prior to randomization and outcome in both arms will be analyzed according the pre-transplant Sorror score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of QOL (FACT-BMT) before and after transplantation at + 100 days, 6 months, 1 year, 2 years between both arms</measure>
    <time_frame>At day 100, 6 months, 1 year and 2 years after allogenic SCT</time_frame>
    <description>The means of change in scores at each time point (day 100, 6 months, 1 year and 2 years after transplantation respectively) from baseline and the confidence intervals of each arm will be presented. To compare the difference in QOL scores between both arms, logistic regression adjusted for covariates and stratification factors will be performed for each time point.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Scientific Endpoint (optional)</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of relapse incidence at two years between MRD positive and negative patients in both arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Scientific Endpoint (optional)</measure>
    <time_frame>2 years</time_frame>
    <description>Comparison of overall survival at two years between MRD positive and negative patients in both arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allogeneic stem cell transplantation from 10/10 HLA matched unrelated donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic stem cell transplantation from haploidentical donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic Stem Cell Transplantation</intervention_name>
    <description>Allogeneic Stem Cell Transplantation</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Acute Myeloid Leukemia (AML) intermediate or high risk according to ELN or Acute
             Lymphoblastic Leukemia (ALL) high risk according to ESMO guidelines in 1. CR or
             AML/ALL in 2. CR, or high risk MDS (according to IPSS-R) in 1. CR or 2. CR.

          2. Patients age: 18 - 70 years at time of inclusion (female and male).

          3. Patients understand and voluntarily sign an informed consent form.

          4. ECOG ≤ 2.

          5. 10/10 HLA-matched unrelated donor and haploidentical (≥ 5/10 and ≤ 8/10 HLA) relative
             matched donor available at least 4 weeks after completion of induction and/or
             consolidation therapy.

          6. Females/Males who agree to comply with the applicable contraceptive requirements of
             the protocol.

        Exclusion Criteria

          1. Severe renal, hepatic, pulmonary or cardiac disease, such as:

               -  total bilirubin, SGPT or SGOT &gt; 3 times upper the normal level

               -  left ventricular ejection fraction &lt; 30 %

               -  creatinine clearance &lt; 30 ml/min

               -  DLCO &lt; 35 % and/or receiving supplementary continuous oxygen

          2. Positive serology for HIV.

          3. Pregnant or lactating women (positive serum pregnancy test).

          4. Age &lt; 18 and ≥ 71 years.

          5. Uncontrolled invasive fungal infection at time of screening (baseline).

          6. Serious psychiatric or psychological disorders.

          7. Participation in another study with ongoing use of unlicensed investigational product
             from 28 days before study enrollment.

          8. Uncontrolled severe autoimmune disease or uncontrolled other malignancy.

          9. Availability of an HLA-identical sibling as donor source.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kröger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf, Department of Stem Cell Transplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolaus Kröger, Prof. Dr.</last_name>
    <phone>+49 (0) 40 7410 55864</phone>
    <email>n.kroeger@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frauke Bach, Dr.</last_name>
    <phone>+49 (0) 40 7410 23182</phone>
    <email>f.bach@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LKH-Univ. Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hildegard Greinix, Prof. Dr.</last_name>
      <email>Hildegard.Greinix@klinikum-graz.at</email>
    </contact>
    <investigator>
      <last_name>Hildegard Greinix, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heinz Sill, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maija Itälä-Remes, Prof. Dr.</last_name>
      <email>maija.itala-remes@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Maija Itälä-Remes, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Urpu Salmenniemi, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Kobbe, Prof. Dr.</last_name>
      <email>kobbe@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Guido Kobbe, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Schröder, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dietrich W. Beelen, Prof. Dr.</last_name>
      <email>dietrich.beelen@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Dietrich W. Beelen, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rudolf Trenschel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jürgen Finke, Prof. Dr.</last_name>
      <email>juergen.finke@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Finke, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hartmut Bertz, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Kroeger, Prof. Dr.</last_name>
      <phone>+49 (0) 40 7410 55864</phone>
      <email>n.kroeger@uke.de</email>
    </contact>
    <investigator>
      <last_name>Nicolaus Kroeger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Wolschke, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Eder, Prof. Dr.</last_name>
      <email>eder.matthias@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Eder, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gernot Beutel, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <email>Matthias.Stelljes@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan-Henrik Mikesch, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris Afanasyev, Prof. Dr.</last_name>
      <email>bmt-director@1spbgmu.ru</email>
    </contact>
    <investigator>
      <last_name>Boris Afanasyev, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Allogeneic Stem Cell Transplantation</keyword>
  <keyword>Matched Unrelated Allogeneic Stem Cell Transplantation</keyword>
  <keyword>Haploidentical Allogeneic Stem Cell Transplantation</keyword>
  <keyword>anti-leukemic activity</keyword>
  <keyword>Cyclophosphamide as GVHD prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

